Xenikos
Latest round
- Series B
Last raised
- May 2018
Total raised
- $35M
Investors
- 4
About Xenikos
V. was founded in 2009 and is headquartered in Nijmegen, Netherlands. The company specializes in immunotherapy solutions, particularly its flagship product, T-Guard™, designed to treat T-cell mediated diseases. The company's CEO and founder is Ypke van Oosterhout, who has a history in the biotechnology sector.V. specializes in immunotherapy solutions, primarily focusing on its flagship product, T-Guard™, a combination of two toxin-loaded anti-T-cell antibodies designed to reset the immune system in T-cell mediated diseases. T-Guard™ addresses critical medical conditions such as grade III/IV steroid-refractory acute graft-versus-host disease (aGVHD) that can occur following allogeneic hematopoietic stem cell transplants. This therapeutic approach seeks to provide a novel treatment avenue for patients with limited options due to the refractory nature of their conditions.'s revenue structure centers around the clinical and therapeutic applications of its product, T-Guard™, particularly in the context of clinical studies and future commercialization. The company engages primarily with healthcare institutions and recruits patients for clinical trials, facilitating the development and testing of its therapeutics. Interactions usually occur through direct engagement with hospitals and clinical research organizations rather than traditional retail channels.V. The company aims to expand its presence in both European and North American markets to enhance access to its innovative therapies.
Who invested in Xenikos
4 investors across 2 rounds
See all investors in Xenikos
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Xenikos
Who invested in Xenikos?
Xenikos has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Xenikos raised?
Xenikos has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Xenikos last raise money?
Xenikos's most recent round on record is a Series B, in May 2018.
What does Xenikos do?
Xenikos is a biotechnology company.
Where is Xenikos headquartered?
Xenikos is headquartered in Nijmegen, Netherlands.
Which VCs invest in companies like Xenikos?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Xenikos's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Xenikos? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.